What Are the Signs and Symptoms of Prostate Cancer?

This content has been reviewed and approved by

Daniel P. Petrylak, MD
Associate Professor of Medicine
Director, Genitourinary Oncology Program
Columbia University Medical Center
 

Unfortunately, prostate cancer does not often produce noticeable signs or symptoms in the early stage of the disease. The absence of symptoms is typically the reason why most prostate cancers already have begun to spread upon diagnosis. This makes annual screening important for men over 50, and earlier and more frequent screening for those with high-risk factors. 

The following are the most common symptoms of prostate cancer. However, each individual may experience symptoms differently. Symptoms may include: 

  • Weak or interrupted urine flow 
  • Frequent urination (especially at night) 
  • Difficulty in urinating or holding back urine 
  • Inability to urinate 
  • Pain or burning during urination 
  • Blood in urine or semen 
  • Nagging pain in the back, hips, or pelvis 
  • Difficulty in having an erection. 

Always consult your physician if you have any or some of these symptoms. 

The symptoms of prostate cancer may also occur with other conditions or medical problems such as benign prostatic hyperplasia (BPH). As men age, the prostate may grow bigger and obstruct the flow of urine, or interfere with sexual function. An enlarged prostate gland (benign prostatic hyperplasia) may require treatment with medicine or surgery to relieve symptoms. BPH is a common prostate condition. It is not cancer. However, BPH can cause many of the same symptoms as prostate cancer.

This content was last reviewed August 15, 2010.
Latest Prostate Cancer News
US FDA panel votes against wider use of Amgen drug

February 8, 2012 — WASHINGTON (Reuters) - An advisory panel on Wednesday recommended that U.S. health regulators reject the use of Amgen Inc's drug Xgeva to delay the spread of prostate cancer to the bone, dimming the chance of a wider use for one of the company's key growth drivers.

FDA staff unsure about new use for Amgen's Xgeva

February 6, 2012 — WASHINGTON (Reuters) - Reviewers from the U.S. Food and Drug Administration said on Monday that they were not sure whether Amgen Inc's Xgeva bone drug should be approved for a wider use of delaying the spread of cancer to the bone.

UK says home-grown cancer pill too costly to use

February 2, 2012 — LONDON (Reuters) - Britain's health cost watchdog NICE sparked a major row on Thursday by snubbing a pricey new prostate cancer pill discovered at the country's top cancer research center, a decision critics said was bad for patients and research.

Select news items provided by Reuters Health